In Q3 2024, Baker Bros. Advisors held 85 positions worth $9.5B. They initiated 4 new positions and exited 27. Their largest holding was BEIGF ($2.4B). Portfolio value grew +24.7% versus the prior quarter.
Frequently asked questions
What stocks did Baker Bros. Advisors own in Q3 2024?
Baker Bros. Advisors held 85 biotech stocks in their 13F portfolio in Q3 2024. Their top positions include BEIGF, INCY, ACAD, SMMT, MDGL. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Baker Bros. Advisors's portfolio worth in Q3 2024?
Baker Bros. Advisors's tracked biotech portfolio was worth $9.5B across 85 positions, with total assets under management of approximately $17B. Portfolio values are based on 13F filings with the SEC.
What did Baker Bros. Advisors buy in Q3 2024?
Baker Bros. Advisors initiated 4 new positions in Q3 2024, including BCAX, IONS, GPCR, WVE. They also increased 16 existing positions.
What did Baker Bros. Advisors sell in Q3 2024?
Baker Bros. Advisors fully exited 27 positions in Q3 2024, including SWTX, SGEN, NTRA, VERU, ITOS and 22 more. They also trimmed 3 existing positions.
Is Baker Bros. Advisors a biotech fund?
Concentrated long-only biotech fund known for taking very large positions in a small number of high-conviction names. The Baker brothers—both trained scientists—focus on deep due diligence of clinical-stage and commercial biotech companies, often holding positions for years through clinical catalysts.
Want AI analysis, insider signals, and catalyst overlays for Baker Bros. Advisors?
View latest Baker Bros. Advisors portfolio →